Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140430

Published: 2020

Journal Articles

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Juan G Valero, PhD, Aranzazu Chamorro-Jorganes, PhD, Katie Walker, PhD, Martina Guerrero-Hernandez, MSc, Vanina Rodriguez, Clara Recasens-Zorzo, MSc, Anna Esteve-Arenys, MSc, Eriong Lee-Verges, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Dolors Colomer, PhD, Armando Lopez-Guillermo, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD, Gael Roue, PhD

Blood (2017) 130 (Supplement 1): 4108.

https://doi.org/10.1182/blood.V130.Suppl_1.4108.4108

Published: 2017

Journal Articles

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

Martina Guerrero-Hernandez, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Anella Yahiaoui, BS, Juan G Valero, PhD, Laura Magnano, MD, Alfredo Rivas-Delgado, MD, Dolors Colomer, PhD, Elias Campo, MD PhD, Armando Lopez-Guillermo, Gael Roue, PhD, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD

Blood (2017) 130 (Supplement 1): 2813.

https://doi.org/10.1182/blood.V130.Suppl_1.2813.2813

Published: 2017

Journal Articles

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Alba Matas-Céspedes, MS, Anna Vidal-Crespo, MS, Vanina Rodriguez, Julio Delgado, MD PhD, Neus Villamor, MD PhD, Gael Roue, PhD, Elías Campo, MD PhD, Dolors Colomer, PhD, Parul Doshi, PhD, Adrian Wiestner, MD PhD, Paul W.H.I. Parren, PhD, Jeroen Lammerts van Bueren, PhD, Patricia Pérez-Galán, PhD

Blood (2014) 124 (21): 4680.

https://doi.org/10.1182/blood.V124.21.4680.4680

Published: 2014

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

Alba Matas-Céspedes, MS, Anna Vidal Crespo, MS, Vanina Rodriguez, Gael Roue, PhD, Armando Lopez-Guillermo, MD, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2013) 122 (21): 378.

https://doi.org/10.1182/blood.V122.21.378.378

Published: 2013

Journal Articles

The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma

Silvia Xargay-Torrent, BS, Monica López-Guerra, PhD, Ifigènia Saborit-Villarroya, PhD, Laia Rosich, BS, Alba Navarro, BS, Neus Villamor, MD, PhD, Marta Aymerich, MD, PhD, Patricia Perez-Galan, PhD, Gael Roue, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD

Blood (2012) 120 (21): 1647.

https://doi.org/10.1182/blood.V120.21.1647.1647

Published: 2012

Journal Articles

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Alba Matas-Céspedes, BS, Anna Vidal-Crespo, BS, Vanina Rodriguez, Gael Roue, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD, Jeroen Lammerts van Bueren, PhD, Joost M Bakker, PhD, Adrian Wiestner, MD, PhD, Paul W.H.I. Parren, PhD, Patricia Perez-Galan, PhD

Blood (2012) 120 (21): 3935.

https://doi.org/10.1182/blood.V120.21.3935.3935

Published: 2012

Journal Articles

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Mark Roschewski, MD, Mohammed Farooqui, DO, Georg Aue, MD, Clifton C. Mo, MD, Janet Valdez, PA, Susan Soto, RN, Patricia Perez-Galan, PhD, Francois Wilhelm, MD, PhD., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1803.

https://doi.org/10.1182/blood.V120.21.1803.1803

Published: 2012

Journal Articles

The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation

Xiameng Sun, BS, Sarah E. M. Herman, PhD, Matthew M. Hsieh, MD, John F. Tisdale, Jichun Chen, PhD, Georg Aue, M.D., Patricia Perez-Galan, PhD, Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 973.

https://doi.org/10.1182/blood.V118.21.973.973

Published: 2011

Journal Articles

The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment

Sarah E. M. Herman, PhD, Xiameng Sun, BS, Joseph J. Buggy, PhD, Georg Aue, M.D., Patricia Perez-Galan, PhD, Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 596.

https://doi.org/10.1182/blood.V118.21.596.596

Published: 2011

Journal Articles

NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo .

Marc A Weniger, PhD, Edgar Gil Rizzatti, MD, PhD, Patricia Perez Galan, PhD, Delong Liu, PhD, Peter J Munson, PhD, Nalini Raghavachari, PhD, Therese White, Megan M Disinski, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 727.

https://doi.org/10.1182/blood.V114.22.727.727

Published: 2009

Journal Articles

Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Expression of a Plasmacytoid Differentiation Program.

Patricia Perez Galan, PhD, Helena Mora Jensen, Marc A Weniger, PhD, Colby M Chapman, Poching Liu, PhD, Nalini Raghavachari, PhD, Arthur L Shaffer, III, PhD, Louis M. Staudt, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 287.

https://doi.org/10.1182/blood.V114.22.287.287

Published: 2009

Journal Articles

The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM.

Patricia Perez Galan, PhD, Colby M Chapman, Federica Gibellini, PhD, Poching Liu, PhD, Nalini Raghavachari, PhD, Mark Roschewski, MD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 412.

https://doi.org/10.1182/blood.V114.22.412.412

Published: 2009

Journal Articles

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

Gael Roue, PhD, Patricia Perez-Galan, PhD, Monica Lopez-Guerra, BS, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD

Blood (2007) 110 (11): 1601.

https://doi.org/10.1182/blood.V110.11.1601.1601

Published: 2007

Journal Articles

BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.

Patricia Perez Galan, PhD, Gael Roue, PhD, Monica Lopez Guerra, BS, Neus Villamor, MD, PhD, Emili Montserrat, MD, PhD, Elias Campo, MD, PhD, Dolors Colomer, PhD

Blood (2007) 110 (11): 3464.

https://doi.org/10.1182/blood.V110.11.3464.3464

Published: 2007

Journal Articles

c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.

Gael Roue, PhD, Patricia Perez Galan, PhD, Neus Villamor, MD, PhD, Elies Campo, MD, Dolors Colomer, PhD

Blood (2005) 106 (11): 4820.

https://doi.org/10.1182/blood.V106.11.4820.4820

Published: 2005

Journal Articles

The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Patricia Perez Galan, PhD, Gael Roue, PhD, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD

Blood (2005) 106 (11): 1490.

https://doi.org/10.1182/blood.V106.11.1490.1490

Published: 2005

NARROW

Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions

Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL

The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma

Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation

The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment

NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo .

Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Expression of a Plasmacytoid Differentiation Program.

The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM.

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.

c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.

The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only